MedPath

To Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal Carcinoma

Recruiting
Conditions
Artificial Intelligence
Otolaryngological Disease
Registration Number
NCT04547673
Lead Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Brief Summary

Nasopharyngeal carcinoma (NPC) occurs at a high frequency in southern China, northern Africa, and Alaska, with a reported incidence of 30 cases per 100 000 in Guangdong Province. Endoscopic examination and biopsy are the main methods used for detection and diagnosis of NPC. Early NPC patients achieve favourable prognoses after concurrent radiotherapy and chemotherapy in compassion with advanced NPC patients.

Here, the investigators focused on the utility of artificial intelligence to detect early NPC, which based on white light imaging (WLI) and Narrow-band imaging (NBI) nasoendoscopic examination. Having access to this unique population provides an unprecedented opportunity to investigate the effect of intelligent system on diverse nasopharyngeal lesions detection and develop a novel Computer-Aided Diagnosis System.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1000
Inclusion Criteria
  • Older than 18 years of age
Exclusion Criteria
  • Refuse to sign the informed consent statement
  • Patients who have contraindications, e.g. coagulation dysfunction, drug allergy.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pathological diagnosisbaseline

All lesions, detected by either WLI or NBI, are biopsied. 2 experienced pathologists, who were blinded to the endoscopic and intelligent assessment, evaluate the pathological nature of the biopsied lesion independently, and 2 professors with over 10 years of experience in Otolaryngology and pathology department are consulted in cases of disagreement.

Secondary Outcome Measures
NameTimeMethod
Lesion rangebaseline

All images in which lesions are pathologically diagnosed as NPC are collected. 2 experienced pathologists, who were blinded to the endoscopic and intelligent assessment, delineated the malignant area in the images independently, and 2 professors with over 10 years of experience in Otolaryngology department are consulted in cases of disagreement.

Trial Locations

Locations (3)

First Affiliated Hospital of Sun Yat-sen University

🇨🇳

Guangzhou, Guangdong, China

Sun Yat-Sen University Cancer Center

🇨🇳

Guangzhou, Guangdong, China

Kiang Wu Hospital

🇨🇳

Macao, Macao, China

First Affiliated Hospital of Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
Yihui Wen, Ph.D
Contact
8613480200660
wenyihui@mail.sysu.edu.cn
Rui He, M.D.
Sub Investigator
Yudong Long, M.D.
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.